ReviewHematology/oncology clinics of North America2016
The Challenge of Primary Central Nervous System Lymphoma.
Review in Hematology/oncology clinics of North America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Lymphomatosis Cerebri Presenting as Steroid-Refractory Demyelinating Disease: A Diagnostic Challenge.Cureus · 2026Article
- A nomogram for predicting the diagnosis of central malignant tumors based on preoperative clinical characteristics and laboratory indicators: a diagnostic study.International journal of surgery (London, England) · 2025Article
- Bilateral Facial Nerve Palsy Revealing Diffuse Large B-Cell Lymphoma With Leptomeningeal Involvement.Cureus · 2025Article
- Blood-brain barrier crossing biopolymer targeting c-Myc and anti-PD-1 activate primary brain lymphoma immunity: Artificial intelligence analysis.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- A disease warranting attention from neurosurgeons: primary central nervous system post-transplant lymphoproliferative disorder.Frontiers in neurology · 2024Article
- Demographics, Pattern of Care & Outcomes of Primary CNS Lymphoma- Experience from a Tertiary Care Cancer Center in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2023Article
- The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.BMC cancer · 2022Article
- Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic.Advanced drug delivery reviews · 2022Review
- Germline Mutations Including the Rare Pathogenic Variant c.3206delC in theChildren (Basel, Switzerland) · 2021Article
- Review
- Primary Central Nervous System Lymphoma Mimicking Longitudinally Extensive Transverse Myelitis.The Neurohospitalist · 2021Article
- Parkinsonism as a late presentation of lymphomatosis cerebri following high-dose chemotherapy with autologous stem cell transplantation for primary central nervous system lymphoma.Journal of neurology · 2020Article
- Cell-Block cytology in diagnosis of primary central nervous system lymphoma: A case report.Medicine · 2020Article
- Comparative study on different therapies on patients with primary central nervous system lymphoma.Saudi journal of biological sciences · 2019Article
- Primary CNS Lymphoma in India: A 17-Year Experience From the All India Institute of Medical Sciences.Journal of global oncology · 2019Article
- Insights from a Case of Vitreoretinal Lymphoma.Ocular oncology and pathology · 2019Article
- When Zoster Virus Hides a Primary Brain Lymphoma.European journal of case reports in internal medicine · 2019Article
- Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.Neoplasia (New York, N.Y.) · 2018Article
- Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.Blood advances · 2018Article
- Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.BioMed research international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Primary central nervous system (CNS) lymphoma is a challenging subtypes of aggressive non-Hodgkin lymphoma. Emerging clinical data suggest that optimized outcomes are achieved with dose-intensive CNS-penetrant chemotherapy and avoiding whole brain radiotherapy. Anti-CD20 antibody-based immunotherapy as a component of high-dose methotrexate-based induction programs may contribute to improved outcomes. An accumulation of insights into the molecular and cellular basis of disease pathogenesis is providing a foundation for the generation of molecular tools to facilitate diagnosis as well as a roadmap for integration of targeted therapy within the developing therapeutic armamentarium for this challenging brain tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.